Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Behavioral Processes Underlying Reward Processing in Depression

This study has been completed.
Sponsor:
Collaborator:
Massachusetts General Hospital
Information provided by:
Affective Neuroscience Laboratory
ClinicalTrials.gov Identifier:
NCT00205933
First received: September 13, 2005
Last updated: December 4, 2007
Last verified: November 2007
  Purpose

The purpose of this project is to use behavioral techniques to investigate emotional processing in subjects with major depression and healthy comparison subjects.


Condition
Major Depressive Disorder
Bipolar Disorder

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Behavioral Processes Underlying Reward Processing in Depression

Resource links provided by NLM:


Further study details as provided by Affective Neuroscience Laboratory:

Enrollment: 78
Study Start Date: April 2004
Study Completion Date: June 2007
Detailed Description:

A promising strategy for parsing the heterogeneity of Major Depressive Disorder is to identify phenotypes characterized by reliable functional abnormalities. Anhedonia, the lack of reactivity to pleasurable stimuli, is considered a trait marker for depression. Using an objective behavioral task this project aims to investigate hedonic capacity in subjects meeting a DSM-IV diagnosis of Major Depressive Disorder.

  Eligibility

Ages Eligible for Study:   18 Years to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Control participants, Participants with MDD, Participants with Bipolar Disorder

Criteria

Inclusion Criteria:

Depressed participants:

  • Right-handed
  • DSM-IV diagnosis of MDD
  • Score of at least 17 on the 21-item HAM-D scale
  • Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
  • No current or past history of MDD with psychotic features
  • Absence of any other Axis I or Axis II diagnosis (Including bipolar disorder and current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded, since dopaminergic alterations have been reported in these conditions. Exclusion of patients with comorbid Axis I or Axis II diagnoses will be necessary as evidence exists of alteration in dopamine receptor density in detached personality and social phobia. The alteration of dopamine in the brain may in turn alter behavior.
  • Absence of significant medical conditions
  • Absence of ECT in the previous 6 months
  • Ability to provide informed consent/authorization

Bipolar participants:

  • Both genders and all ethnic origins
  • Age between 18 and 64
  • Right-handed
  • DSM-IV diagnosis of Bipolar Disorder I or II
  • Score of at least 17 on the 21-item Hamilton Depression Rating Scale (HAM-D)
  • Absence of any psychotropic medications for at least 2 weeks (6 months for dopaminergic drugs (including methylphenidate), 6 weeks for fluoxetine, and 4 weeks for neuroleptics and benzodiazepines because of longer half-lives.)
  • No current or past history of MDD with psychotic features
  • Absence of any other Axis I or Axis II diagnosis (Including current or lifetime history of alcohol or substance abuse or dependence.) Particularly, subjects with a history of alcoholism and substance abuse will be excluded.
  • Absence of significant medical conditions
  • Absence of ECT in the previous 6 months
  • Ability to provide informed consent/authorization

Control Participants:

  • Right-handed
  • Absence of medical, neurological, and psychiatric illness (including alcohol and substance abuse), as assessed by the SCID
  • Absence of any medications for at least 2 weeks
  • Informed consent/authorization

Exclusion Criteria:

  • Left-handed/ambidextrous
  • Evidence of neurological illness
  • Current alcohol or substance abuse
  • Serious suicide or homicide risk
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00205933

Locations
United States, Massachusetts
The Depression Clinical and Research Program, Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Affective Neuroscience Laboratory, Department of Psychology, Harvard University
Cambridge, Massachusetts, United States, 02138
Sponsors and Collaborators
Affective Neuroscience Laboratory
Massachusetts General Hospital
Investigators
Principal Investigator: Diego A Pizzagalli, PhD Harvard University
  More Information

Additional Information:
No publications provided

Responsible Party: Diego Pizzagalli, Principal Investigator, Harvard University
ClinicalTrials.gov Identifier: NCT00205933     History of Changes
Other Study ID Numbers: 2003-P-000994
Study First Received: September 13, 2005
Last Updated: December 4, 2007
Health Authority: United States: Federal Government

Keywords provided by Affective Neuroscience Laboratory:
Depression
Bipolar Disorder
Reward Processing

Additional relevant MeSH terms:
Bipolar Disorder
Depression
Depressive Disorder
Depressive Disorder, Major
Disease
Affective Disorders, Psychotic
Behavioral Symptoms
Mental Disorders
Mood Disorders
Pathologic Processes

ClinicalTrials.gov processed this record on November 24, 2014